Gastrointestinal Cancer News

CHICAGO — Alexandre Lebeaut, MD, head of research and development at Ipsen Pharmaceuticals, spoke with HemOnc Today at ASCO Annual Meeting about key study results the company presented and promising investigational agents in its pipeline.

CHICAGO — Ramucirumab was well tolerated and associated with low rates of discontinuation among patients with advanced hepatocellular carcinoma who were intolerant to first-line treatment with sorafenib, according to data presented at the ASCO Annual Meeting.

The FDA approved trastuzumab-anns for the treatment of HER2-overexpressing breast cancer, as well as metastatic gastric or gastroesophageal junction adenocarcinoma.

CHICAGO — Laparoscopic surgery for colorectal liver metastases nearly equaled or surpassed open surgery for almost all outcomes, according to results of the randomized, phase 3 OSLO-COMET trial presented at ASCO Annual Meeting.

CHICAGO — Anthony “Andy” Boral, MD, PhD, chief medical officer at Blueprint Medicines, spoke with HemOnc Today at ASCO Annual Meeting about key study results the company presented and the investigational agents in its pipeline.

CHICAGO — At the ASCO Annual Meeting, HemOnc Today Next Gen Innovator Kim Reiss Binder, MD, assistant professor of medicine at the Hospital of the University of Pennsylvania, discusses an ongoing clinical trial assessing platinum sensitivity as a biomarker of response to a novel treatment combination for advanced pancreatic ductal adenocarcinoma.

CHICAGO — Patients with unresectable, metastatic colorectal cancer derived significant PFS and OS benefits from upfront FOLFOXIRI chemotherapy and bevacizumab, followed by reintroduction of the regimen after progressive disease, compared with preplanned consecutive FOLFOX-bevacizumab and FOLFIRI-bevacizumab, according to updated results of the randomized phase 3 TRIBE2 study presented at ASCO Annual Meeting.

CHICAGO — Laparoscopic surgery was associated with similar OS and RFS rates compared with open-resection surgery in patients with colorectal liver metastases, according to findings presented at the ASCO Annual Meeting.

Lynch syndrome screening among patients with newly diagnosed colorectal cancer was significantly less efficient in patients after age 70 to 75 years, and ending screening in patients aged older than 80 years may be more reasonable than universal screening, according to research findings published in Annals of Internal Medicine.

CHICAGO — Patients with previously treated advanced hepatocellular carcinoma demonstrated reduced risk for death and improved PFS with the addition of pembrolizumab vs. placebo to best supportive care, according to findings from the randomized phase 3 KEYNOTE-240 study presented at ASCO Annual Meeting.